Sohanya Roshan Cheng - 30 Jun 2021 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
SVP Sales & Commercial Ops
Signature
/s/ Nancy Smith as Attorney-in-Fact for Sohanya Cheng
Issuer symbol
KPTI
Transactions as of
30 Jun 2021
Net transactions value
$0
Form type
4
Filing time
01 Jul 2021, 16:33:12 UTC
Previous filing
11 Jun 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +7,500 $0.000000 7,500 30 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Nonstatutory Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 30 Jun 2021 Common Stock 125,000 $10.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on June 7, 2022, the first anniversary of Ms. Cheng's date of hire, with the remaining 50% vesting on June 7, 2023.
F2 This option was granted on June 30, 2021. The shares underlying this option vest as to 25% of the shares on June 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.